Efficacy of Secukinumab in Psoriasis: Post Hoc Gender-Wise Analysis of the SUPREME Study.

PURPOSE

Psoriasis, a common systemic inflammatory disorder, presents with gender-related differences in the quality of life (QoL) and treatment outcomes. This post hoc analysis from the Phase 3b SUPREME study explored gender-related differences in patient characteristics and efficacy of secukinumab 300 mg on Psoriasis Area and Severity Index (PASI) 75/90/100 and impact on QoL using the Dermatology Life Quality Index (DLQI) in patients with moderate to severe psoriasis through week 24.

PATIENTS AND METHODS

The proportion of patients achieving PASI 75/90/100 was computed using a nonresponder imputation approach. Differences between cohorts were analyzed using a logistic regression model. The mean change from baseline in DLQI was computed using the Wilcoxon test.

RESULTS

Among the 433 patients (males: 71.6%), females had a higher DLQI than males at baseline (13.1 vs 9.5; <0.0001). Males had a slightly higher response for PASI 90 than females at week 16 (80.7% vs 78.1%; =0.0779) and 24 (83.2% vs 79.7%; =0.0319). No differences were observed between genders in PASI 100/75 responses at week 24. Both genders showed an improvement in DLQI with secukinumab at week 24 (-10.9 vs -8.1, respectively, in females vs males; =0.0004).

CONCLUSION

In summary, secukinumab was effective in the treatment of psoriasis, irrespective of gender.